Kim Wohlwend, MSN, APRN, FNP-BC, PMHNP-BC
Dual ANCC board-certified Family Nurse Practitioner and Psychiatric-Mental Health Nurse Practitioner. Prescribes both Wegovy and Zepbound from our Papillion, Nebraska office and by telehealth in 16 states.
Quick Answer
Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved once-weekly injections for chronic weight management. Zepbound has shown numerically higher average weight loss in separate pivotal trials and is the only weight-loss medication FDA-approved for obstructive sleep apnea. Wegovy is the only one FDA-approved to reduce cardiovascular event risk in adults with established heart disease. The right choice depends on your medical history, tolerability, insurance, and goals.
At a Glance
Wegovy vs Zepbound, side by side.
The fastest read of the two medications. The sections that follow expand on mechanism, efficacy, side effects, dosing, and cost in more clinical detail. For our broader weight-loss approach beyond the medication choice, see our medical weight loss program page.
| Wegovy | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist (single) | GIP and GLP-1 receptor agonist (dual) |
| Route | Once-weekly subcutaneous injection, or daily oral tablet | Once-weekly subcutaneous injection |
| Dose range | 0.25mg to 2.4mg | 2.5mg to 15mg |
| Titration interval | Every 4 weeks (minimum) | Every 4 weeks (minimum) |
| Avg weight loss (pivotal trial) | ~14.9% at 2.4mg, 68 weeks (STEP-1) | ~20.9% at 15mg, 72 weeks (SURMOUNT-1) |
| FDA indication: weight management | Yes. Adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity | Yes. Adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity |
| FDA indication: cardiovascular risk reduction | Yes. In adults with established cardiovascular disease and obesity or overweight (SELECT trial) | No |
| FDA indication: obstructive sleep apnea | No | Yes. Moderate-to-severe OSA in adults with obesity (SURMOUNT-OSA trial) |
| Most common side effect | Nausea (about 44% in trials) | Nausea (about 29% in trials) |
| Cash retail price (approx.) | $1,000 to $1,350 per month | $1,000 to $1,300 per month |
| Medicare GLP-1 Bridge coverage (2026 to 2027) | Yes. $50/month for eligible Part D beneficiaries | Yes. $50/month for eligible Part D beneficiaries |
How to read this table. STEP-1 and SURMOUNT-1 were separate trials with different populations and durations, so the weight-loss percentages are not a direct head-to-head comparison. The single direct head-to-head trial, SURPASS-2 in type 2 diabetes, favored tirzepatide on glycemic and weight endpoints. Individual response varies. Cardiovascular and OSA indications can be decisive when a patient has those comorbidities.
How They Work
Single vs dual incretin pathway.
Both medications belong to a class of drugs called incretin mimetics. They mimic gut hormones that the body releases after meals to signal fullness and regulate blood sugar. The difference is how many receptors each drug activates.
Semaglutide: GLP-1 only
Wegovy activates only the GLP-1 receptor. GLP-1 (glucagon-like peptide 1) is an incretin hormone the small intestine releases after eating. It slows gastric emptying, signals fullness in the hypothalamus, suppresses glucagon, and improves insulin secretion. The result is reduced appetite, smaller portions, and more stable blood sugar between meals.
Wegovy is available as both a once-weekly subcutaneous injection (the original 2.4mg pen) and a daily oral tablet. The active ingredient is the same; absorption, dosing scale, and titration differ between the formulations.
Tirzepatide: GLP-1 plus GIP
Zepbound activates both the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone with overlapping but distinct effects on insulin secretion, glucagon regulation, and fat metabolism. Activating both pathways simultaneously appears to produce more potent appetite suppression and more weight loss than GLP-1 activation alone, though the full mechanistic picture is still being studied.
Clinical Efficacy
How much weight do patients actually lose?
In pivotal trials of patients with obesity and without diabetes, Wegovy 2.4mg produced about 14.9 percent average body-weight reduction over 68 weeks (STEP-1), and Zepbound 15mg produced about 20.9 percent average body-weight reduction over 72 weeks (SURMOUNT-1). Trials were not run head-to-head for weight loss, so the numbers are not directly comparable. The only direct head-to-head comparison (SURPASS-2, in type 2 diabetes) favored tirzepatide on both weight and glycemic endpoints.
The headline numbers above describe averages across thousands of trial participants. They do not describe what any individual patient will experience. About 10 to 15 percent of patients respond meaningfully more than the average. A similar fraction respond less, sometimes substantially less. Identifying which group a given patient falls into is something only treatment over time reveals.
What matters more than the headline percentage:
- Trajectory over months, not weeks. Both medications produce gradual, sustained loss, often continuing throughout the first year of treatment and plateauing thereafter.
- Body composition. Some of the weight lost on either drug is lean body mass. Protein-forward nutrition and resistance training during treatment meaningfully protect muscle.
- Comorbidity response. Improvements in blood pressure, lipids, fasting glucose, sleep apnea severity, and joint pain often track with weight loss and matter as much as the number on the scale.
- Durability after stopping. Most patients regain a substantial portion of lost weight within 12 months of discontinuation, regardless of which medication was used.
The choice between Wegovy and Zepbound is rarely "which drug gives me more weight loss on paper" and more often "which drug works for my body, my comorbidities, my tolerability, and my insurance."
Side Effects and Tolerability
What does each drug feel like to take?
Both medications share a similar side-effect profile dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Most side effects occur during dose escalation, are mild to moderate, and improve with time. In separate clinical trials, nausea was reported in roughly 44 percent of Wegovy patients and 29 percent of Zepbound patients, but these numbers come from different trial populations and titration schedules and should not be over-interpreted.
Shared class effects to know about
Both drugs carry a boxed warning about thyroid C-cell tumors observed in rodents. Human relevance is unknown. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both can cause acute pancreatitis (uncommon), gallbladder disease, acute kidney injury related to volume loss from GI symptoms, and rare cases of diabetic retinopathy progression in patients with diabetes.
Because both medications slow gastric emptying, both can affect the absorption of oral medications and increase the risk of pulmonary aspiration during anesthesia. Both should be discussed with your anesthesiologist before any elective procedure, and current guidance often involves holding the dose for one to two weeks before surgery.
What patients tell us
Tolerability is the strongest predictor of which medication a patient will stay on long-term, and tolerability is highly individual. Some patients do better on semaglutide. Others do better on tirzepatide. We do not have a reliable way to predict in advance which will be the case for a given patient. Slow titration, smaller meals, adequate protein and hydration, and avoiding high-fat or large-volume meals all reduce GI symptoms regardless of which drug you use.
When tolerability becomes a problem on one drug, switching to the other is reasonable, and we discuss this openly with patients. See our guide to the GLP-1 weight loss stall for what we look at before changing medications.
Dosing Schedule
How are they titrated?
Both medications use a stepwise titration with a minimum of four weeks at each dose before advancing. Wegovy steps from 0.25mg to 0.5mg to 1mg to 1.7mg to 2.4mg over at least 16 weeks. Zepbound steps from 2.5mg to 5mg to 7.5mg to 10mg to 12.5mg to 15mg over at least 20 weeks. Many patients reach an effective, well-tolerated dose before the maximum and never need to escalate further.
Wegovy titration
The Wegovy injection schedule is fixed by the manufacturer in a pen format: 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, each for four weeks. Patients who tolerate each step on schedule reach the maintenance 2.4mg dose at week 17. Patients who experience meaningful GI side effects at a given step can stay there longer or step down one level. Slow is fine. The goal is the highest dose you tolerate well, which is not always 2.4mg.
The oral formulation of Wegovy uses a separate titration scale because oral semaglutide has much lower bioavailability than the injection. We discuss whether the oral form is a fit at your visit and write the appropriate titration plan for whichever formulation we choose.
Zepbound titration
The Zepbound schedule starts at 2.5mg and adds three additional intermediate steps before reaching maximum. The six available doses (2.5, 5, 7.5, 10, 12.5, 15mg) give more headroom for patients who need higher potency and more granularity for patients who tolerate slow advancement. Many patients reach a well-tolerated, effective maintenance dose at 10mg or 12.5mg and do not escalate to 15mg.
What this means in practice
Expect the first three to four months to be titration, not maintenance. Substantial weight loss usually accelerates after reaching an effective dose, not in the first weeks of treatment. Some patients see a few pounds of loss during early titration; others see very little until they reach a higher dose. Both patterns are normal and do not predict the long-term result.
Cost and Insurance
What do they actually cost?
Cash retail prices are roughly $1,000 to $1,350 per month for Wegovy and roughly $1,000 to $1,300 per month for Zepbound. Both manufacturers offer direct-to-patient and savings programs that can reduce costs for eligible patients. Commercial insurance coverage varies widely. Medicare Part D patients may qualify for $50 per month under the Medicare GLP-1 Bridge Program. Our clinical visit fees ($60 initial, $60 per month) are separate from medication cost.
Commercial insurance coverage
Coverage for Wegovy and Zepbound under commercial plans has expanded substantially since 2024 but remains uneven. Many plans cover one but not the other, often based on negotiated pricing with the manufacturer. Most plans require prior authorization, which typically asks for documented BMI, weight-related comorbidities, and a record of prior lifestyle intervention. When a plan denies coverage, we routinely help patients submit a clinical letter of medical necessity. If insurance denies a GLP-1, our guide on what to do when insurance denies Wegovy or Zepbound covers the appeals process.
Manufacturer savings and direct-pay programs
Novo Nordisk offers a Wegovy savings card for eligible commercially insured patients and runs NovoCare Pharmacy as a direct-to-patient option that can be meaningfully less than retail. Eli Lilly offers a Zepbound savings card for eligible commercially insured patients and runs LillyDirect as a direct-to-patient option. Both programs have eligibility rules and frequently change pricing. We confirm current costs at the visit when we choose a pharmacy.
Our clinical fees are flat and separate
Self-pay clinical visits are $60 for the initial evaluation and $60 per month for ongoing care, regardless of which medication you take. The monthly fee includes refills, follow-up visits, and secure messaging through the patient portal. Medication cost is paid directly to the pharmacy. We do not mark up medication or accept payment from manufacturers. Cancel anytime.
Medicare Coverage
What about Medicare patients?
Beginning July 1, 2026, Medicare Part D beneficiaries who meet the program's BMI and condition criteria can access Wegovy, Zepbound, or Foundayo for $50 per month through the CMS Medicare GLP-1 Bridge Program. The program is currently scheduled through December 31, 2027. Patients should review eligibility, confirm Part D enrollment, and submit prior authorization with their plan.
The Medicare GLP-1 Bridge Program is the most significant change to Medicare weight-management coverage in the program's history. Prior to the Bridge, Medicare Part D explicitly excluded coverage of medications used solely for weight loss, leaving Medicare patients to pay roughly $1,000 per month cash or go without. The Bridge changes that for an 18-month demonstration window.
Bridge eligibility is more restrictive than the general FDA label for Wegovy or Zepbound. There are three BMI-based tiers, each with its own condition requirements. We cover the eligibility tiers, prior authorization process, pricing scenarios, and a free eligibility calculator on our dedicated Bridge service page.
The Medicare GLP-1 Bridge Program is its own page.
If you are a Medicare Part D beneficiary considering Wegovy or Zepbound, the Bridge service page covers everything specific to Medicare coverage: eligibility tiers, prior authorization, what to do if you are already paying cash, and how to enroll. We built a free, private eligibility calculator to estimate your fit in about 60 seconds. No health information is transmitted.
Choosing Between Them
Who is each medication a better fit for?
Generalizations only. The actual decision is made with a clinician who has reviewed your medical history, current medications, lab work, and insurance coverage. Neither medication is universally superior. Patients do well on both; the right one for you is the one your body tolerates that your plan will cover.
If you have established cardiovascular disease
- You have a documented history of heart attack, stroke, or symptomatic peripheral artery disease, and you are overweight or have obesity. Wegovy carries the only FDA indication in this class for cardiovascular risk reduction in this population.
- Your commercial insurance covers Wegovy but not Zepbound. Coverage parity is improving but is still plan-by-plan.
- You tolerated semaglutide well in a prior course (Ozempic for diabetes, Wegovy previously) and are returning to GLP-1 treatment.
- You prefer staying within Novo Nordisk's pharmacy and savings ecosystem (NovoCare Pharmacy, manufacturer savings card).
If you have moderate-to-severe sleep apnea
- You have moderate-to-severe obstructive sleep apnea documented on a sleep study, and you have obesity. Zepbound carries the only FDA indication in this class for OSA in this population.
- You have type 2 diabetes alongside obesity. The SURPASS-2 head-to-head trial in type 2 diabetes favored tirzepatide on glycemic and weight endpoints.
- You plateaued on maximum-dose semaglutide (Wegovy 2.4mg) and want more headroom at the top of the dose range.
- Your commercial insurance covers Zepbound preferentially, or Eli Lilly's LillyDirect pricing is meaningfully better than NovoCare for you.
When neither may be the right starting point
Both Wegovy and Zepbound are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Both are inappropriate during pregnancy and breastfeeding. Both require caution in patients with a history of pancreatitis, severe gastroparesis, or active eating disorders. For patients in any of these categories, or for patients who simply prefer non-GLP-1 options, alternative weight-management approaches exist and we discuss them at a visit.
How We Choose
Our approach is neutral and clinical.
We prescribe both Wegovy and Zepbound and we have no financial relationship with Novo Nordisk or Eli Lilly. We do not accept payment, speaking fees, or consulting income from pharmaceutical companies. The choice between the two medications is made with you, based on your medical history, comorbidities, insurance, prior treatment history, and tolerability.
What we evaluate before prescribing either medication:
- Current and historical BMI, weight trajectory, and prior weight-management interventions
- Comorbid conditions, especially cardiovascular disease, diabetes, sleep apnea, and chronic kidney disease
- Personal and family history of medullary thyroid cancer and MEN 2
- History of pancreatitis, gallbladder disease, gastroparesis, eating disorders, and depression
- Current medications, especially insulin, sulfonylureas, and oral contraceptives
- Baseline labs, including fasting glucose, HbA1c, lipid panel, liver and kidney function, thyroid function, and pregnancy testing where appropriate
- Insurance coverage, prior authorization requirements, and out-of-pocket cost considerations
What we do once treatment starts:
- Brief check-ins every four to eight weeks during titration, then every one to three months on maintenance
- Side-effect monitoring and dose adjustment as needed; slow titration when GI symptoms are bothersome
- Periodic lab work to monitor metabolic, kidney, and liver function
- Ongoing nutrition and lifestyle counseling, with emphasis on protein intake, resistance training, and sleep
- Honest conversation about what to expect: gradual loss, plateaus, and the long-term nature of treatment
Our broader medical weight loss program is described on the medical weight loss page. If you would like a deeper look at either medication individually, see our Wegovy page or our Zepbound page.
Where we prescribe Wegovy and Zepbound
We see patients in-person at our office in Papillion, Nebraska, serving the Omaha metro (including Bellevue, La Vista, Gretna, Elkhorn, Millard, and Council Bluffs). We also prescribe Wegovy and Zepbound by secure telehealth for adults physically located in any of the 16 states we serve: Nebraska, Iowa, Kansas, Colorado, Arizona, Illinois, Utah, Idaho, New Mexico, Kentucky, Montana, North Dakota, South Dakota, Vermont, New Hampshire, and Maine. Labs and basic vitals are obtained locally; the clinical visit is conducted by video.
Frequently Asked Questions
Wegovy vs Zepbound: common questions.
Is Zepbound better than Wegovy for weight loss?
In separate pivotal clinical trials, Zepbound (tirzepatide) showed numerically higher average weight loss than Wegovy (semaglutide): about 20.9 percent at 15mg over 72 weeks in SURMOUNT-1, versus about 14.9 percent at 2.4mg over 68 weeks in STEP-1. These were not head-to-head weight-loss trials. The single direct head-to-head trial, SURPASS-2 in type 2 diabetes, favored tirzepatide on glycemic and weight endpoints. Individual response varies widely, and the right drug depends on tolerability, cost, insurance, and your medical history.
Which has fewer side effects, Wegovy or Zepbound?
Both medications share a similar side-effect profile dominated by gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation). In clinical trials, nausea was reported in roughly 44 percent of patients on Wegovy versus 29 percent on Zepbound, but this comparison spans different trial populations and titration schedules and should not be read as a definitive head-to-head tolerability comparison. In practice, individual tolerability varies and is the strongest predictor of which medication a given patient will stay on long-term.
Can I switch between Wegovy and Zepbound?
Yes. Switching between Wegovy and Zepbound is a common request, usually for patients who plateau on maximum-dose Wegovy (2.4mg), experience tolerability issues, or face an insurance coverage change. When switching, the new medication is generally restarted at a low dose rather than matched dose-for-dose, because the two drugs differ in mechanism (tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is GLP-1 only) and potency. Expect a brief re-titration period.
What is the difference between semaglutide and tirzepatide?
Semaglutide (Wegovy, Ozempic) is a single-receptor GLP-1 agonist. Tirzepatide (Zepbound, Mounjaro) is a dual-receptor agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone that complements GLP-1 activity on appetite regulation, insulin secretion, and fat metabolism. The dual mechanism appears to explain the higher numerical efficacy observed with tirzepatide in clinical trials, though direct head-to-head weight-loss trials remain limited.
Will Medicare cover Wegovy or Zepbound?
Yes, both Wegovy and Zepbound are covered under the new Medicare GLP-1 Bridge Program for $50 per month, effective July 1, 2026 through December 31, 2027. Medicare Part D beneficiaries must meet one of three BMI-based eligibility tiers and use the medication alongside structured nutrition and physical activity. Prior authorization through your Part D plan is required. See our Medicare GLP-1 Bridge service page for full eligibility details and the free eligibility calculator.
Are Wegovy and Zepbound approved for different conditions?
Yes. Both are FDA-approved for chronic weight management, but each has a unique additional indication. Wegovy is the only weight-management GLP-1 with an FDA indication for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial. Zepbound is the only weight-management GLP-1 with an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. These differences can drive the choice when a patient has one of those comorbidities.
How much do Wegovy and Zepbound cost without insurance?
Approximate cash retail prices are roughly $1,000 to $1,350 per month for Wegovy and roughly $1,000 to $1,300 per month for Zepbound. Both manufacturers offer direct-to-patient and savings programs that can reduce these costs for eligible patients. Patients with Medicare Part D may qualify for $50 per month under the Medicare GLP-1 Bridge Program. Our clinical visit fees are separate: $60 initial visit, then $60 per month for ongoing care.
Do I have to stay on Wegovy or Zepbound forever?
Both medications are indicated for chronic weight management, meaning long-term use. Clinical trial data and clinical experience consistently show that most patients regain a substantial portion of their lost weight within a year of stopping either medication. Obesity is a chronic relapsing condition, and most patients require ongoing pharmacologic support to maintain weight loss and the associated cardiometabolic benefits. We discuss long-term planning openly with every patient before starting either medication.
Not sure which is right for you?
We will review your medical history, current medications, comorbidities, insurance coverage, and goals at the initial visit, then recommend a path. In-person in Papillion, Nebraska or telehealth in 16 states. Both medications prescribed; neither preferred by default.
Schedule a Weight Loss Consultation Or See Medicare GLP-1 Bridge